• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Evaluating and Treating Tremor

Evaluating and Treating Tremor

September 1, 2009
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD

While tremor is traditionally thought of as a neurological issue, the symptom pops up often in psychiatric practice, and some basic knowledge of its diagnosis and treatment comes in handy.

Case vignette: A 67-year-old woman whom I’ll call “Paula” came to see me for depression and anxiety. She ascribed her depression to her belief that neighbors were coming into her apartment and stealing things—which her daughter assured me was implausible. Her memory and cognitive processing were normal otherwise, and her PCP had already obtained an array of labs and a head CT to rule out a contributing medical illness. I provisionally diagnosed her with depression with psychotic features, and I treated her with a combination of Celexa (citalopram) and low dose Risperdal (risperidone), with Ativan (lorazepam) on an as needed basis. On Paula’s next visit, she held out her hands in front of me and said, “Doctor, I’ve gotten even shakier.” I did notice a fine tremor, but further questioning revealed that her depression and paranoia had improved markedly. Nonetheless, she interpreted her “shakiness” to mean that she was worse.

So what was causing Paula’s tremor? Anxiety? Celexa? Risperdal? A neurological condition such as Parkinson’s disease? Or was this “essential tremor”?

By far, the most common cause of tremor is essential tremor, also called “benign familial tremor.” (See Smaga S, Am Fam Physician 2003;68:1545-1552, for a helpful review of the differential diagnosis of tremor). It generally begins in the 50s, is familial in up to 60% of cases, and usually presents as a symmetrical fast, fine tremor of the wrist most visible when the patient stretches the arms in front of you. It is gradually progressive, and sometimes affects the head, causing either yes-yes or no-no head movements. Essential tremor is typically a constant tremor, but may wax and wane, and famously improves transiently with alcohol ingestion.

Upon careful questioning, it turned out that Paula’s father had a tremor for much of his life, and in fact Paula said she had a tremor for many years. Studies have shown that essential tremor often goes unrecognized because it can be very mild—in fact, about 50% of people with essential tremor are unaware of it (Eible RJ, Mov Disord 1998;13:457-464).

Drug-induced tremor is also common and often looks just like essential tremor. Psychiatric drugs that can cause tremor include the SSRIs, the tricyclic antidepressants, lithium, and Depakote (divalproex sodium). (For a recent review of tremor in psychiatric practice, see Arbaizar B et al., Psych Clin Neurosc 2008;62:638-645.) Antipsychotics, especially the first generation antipsychotics, also can cause tremor, but this tremor is distinct from other tremors in that it mimics the tremor of Parkinson’s disease it is worse at rest, and it is a slower, “coarse” tremor. Tremors are often technically described in terms of “frequency” (the speed of the tremor) and “amplitude” (the breadth of the tremor).

Thus, essential tremor and most drug induced tremors are of high frequency and low amplitude, while a Parkinsonian tremor is of lower frequency and higher amplitude.

Differentiating essential tremor from drug-induced tremor is not easy. Did it clearly begin after the patient started taking the drug? Did it go away when the patient had a gap in compliance? Is the tremor more prominent an hour or so after ingesting the drug (often seen in lithium-induced tremor)? “Yes” answers support a drug-induced tremor.

While my patient Paula did, indeed, have a history of essential tremor, it was also clear that her tremor had worsened since she began Celexa and Risperdal. In addition to her fine postural tremor (consistent with essential tremor), I noticed that she had a coarse resting tremor of her wrists, typical of a neurolepticinduced tremor.

My solution was to discontinue the Risperdal, with the intention of replacing it with Seroquel if her paranoia returned. Her tremor improved back to her baseline, and luckily the combination of the Celexa and lorazepam kept her psychiatric symptoms at bay.

Another kind of tremor-related symptom deserves special mention: antidepressant-induced jitteriness. In 1990, an influential case series of six patients who developed intense suicidal ideation after treatment with Prozac (fluoxetine) brought this issue to our attention (Teicher MH, et al., Am J Psychiatry 1990;147:207-210). Since then, case studies have been published associating SSRIs and other antidepressants with what has variously been termed: jitteriness, akathisia, shakiness, activation, and agitation.

Recently, a group of psychiatrists conducted a systematic review of all 107 articles they could locate describing antidepressant-induced jitteriness/anxiety (Sinclair LI et al., Br J Psychiatry 2009; 194:483-490). Since there is no agreedupon definition of AD-induced jitteriness, the published incidence rates are all over the map, ranging from 4% to

65%. The two antidepressants most likely to cause jitteriness were Prozac and imipramine (perhaps merely because they were the most studied in relation to jitteriness), although it has been described for other tricyclics and other SSRIs including Zoloft and Paxil. The syndrome is particularly likely in patients with panic disorder, and somewhat less so in depression. It generally begins within the first two weeks of treatment. Trying to distinguish jitteriness from akathisia has proven very difficult, and these reviewers concluded that they may be one and the same entities. Regarding the risk of suicide, an FDA-commissioned analysis of antidepressant clinical trials in children and adolescents found an elevated risk of suicidal behaviors among youth who experienced symptoms of “activation” (Hammed T www.fda.gov/ohrms/dockets/ac/04/slides/20044065S1_08_FDA-Hammad.ppt). In

Pfizer’s clinical trials of sertraline for depression in children, aggression, agitation, and akathisia led to study discontinuation in eight of 189 patients taking sertraline compared to 0 of 184 patients taking placebo, a statistically significant difference (Wagner KD et al., JAMA 2003; 290:1033-1041).
Management of Tremor

The management of tremor and jitteriness depends on the cause. When it is clearly caused by a drug, discontinuing the offending agent is the best solution, but often a drug works so well that the patient prefers to stay on it. Antidotes to tremor include the following (for references, see the review article Arbaizar B et al., Psych Clin Neurosc 2008;62:638-645).

Beta-blockers. Propranolol (Inderal) is usually used, starting at 10mg BID or TID; some patients require up to 40 mg TID. You can also try the extended release version, Inderal LA, which has the advantage of once-a-day dosing; the beginning dose is 60 mg QD. Warn patients about the common betablocker side effects of fatigue and postural light-headedness.

Benzodiazepines. Both alprazolam and clonazepam have been shown to be helpful for tremor, and are also helpful (as are all the other benzos) for ADinduced jitteriness.

Primidone (Mysoline). Primidone is an anti-seizure drug that it also effective for essential tremor. Its mechanism of action is unknown. Start at 12.5-25 mg QHS, and increase gradually as needed. Effective doses range from 50-250 mg QD, usually given at bedtime because of the side effect of sedation.

Topiramate (Topamax). Topiramate has been shown to be more effective than placebo for essential tremor. The starting dose is 25 mg/day, which may need to be increased up to 200-400 mg/day.

Gabapentin (Neurontin).Somewhat less effective than the options already described, gabapentin sometimes eases both tremor and anxiety, but the effective dose varies widely, with a suggested maintenance dose of 1200-3600 mg/day.

TCPR Verdict:

When faced with tremor, think essential vs. drug-induced.

 
General Psychiatry
KEYWORDS anxiety_disorder depressive_disorder
    www.thecarlatreport.com
    Issue Date: September 1, 2009
    SUBSCRIBE NOW
    Table Of Contents
    Thinking like a Neurologist
    Restricting Drug Samples May Reduce Costs
    N-Acetylcysteine Effective For Trichotillomania
    Treating Headaches in Psychiatry
    Evaluating and Treating Tremor
    Role of Depression “Risk Gene” Questioned
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.